Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 156 points (1.0%) at 15,978 as of Friday, Dec. 6, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 2,203 issues advancing vs. 732 declining with 103 unchanged. The Health Care sector currently sits up 0.5% versus the S&P 500, which is up 0.9%. Top gainers within the sector include Boston Scientific ( BSX), up 4.2%, Cigna ( CI), up 2.5%, Intuitive Surgical ( ISRG), up 2.2%, Thermo Fisher Scientific ( TMO), up 2.0% and Agilent Technologies ( A), up 2.0%. A company within the sector that fell today was Teva Pharmaceutical Industries ( TEVA), up 0.6%. TheStreet would like to highlight 5 stocks pushing the sector higher today: 5. Biogen Idec ( BIIB) is one of the companies pushing the Health Care sector higher today. As of noon trading, Biogen Idec is up $7.20 (2.5%) to $292.12 on average volume. Thus far, 465,121 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $283.00-$292.49 after having opened the day at $289.55 as compared to the previous trading day's close of $284.92. Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $67.5 billion and is part of the drugs industry. The company has a P/E ratio of 40.1, above the S&P 500 P/E ratio of 17.7. Shares are up 95.3% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.